| Literature DB >> 35982781 |
Xiaoyu Guo1, Yilong Li1, Hui Lin2, Long Cheng1, Zijian Huang1, Zhitao Lin1, Ning Mao1, Bei Sun1, Gang Wang1, Qiushi Tang3.
Abstract
Background/Purpose: Currently, there are no effective tools to accurately assess acute biliary pancreatitis (ABP) risk in patients with gallstones. This study aimed to develop an ABP risk nomogram in patients with symptomatic gallstones.Entities:
Keywords: acute biliary pancreatitis; gallstones; nomogram; predictors; receiver operating characteristic curves
Mesh:
Year: 2022 PMID: 35982781 PMCID: PMC9380850 DOI: 10.3389/fcimb.2022.935927
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
Characteristics of patients in the study and validation cohorts.
| Variables | Study cohort(n=229) | Validation cohort(n=96) |
|
|---|---|---|---|
| Age (year) | |||
| <50 | 104 (45.4%) | 50 (52.1%) | |
| ≥50 | 125 (54.6) | 46 (47.9%) | 0.272 |
| Sex | |||
| Female | 148 (64.6%) | 52 (54.2%) | |
| Male | 81 (35.4%) | 44 (45.8%) | 0.77 |
| Alcoholic history | |||
| No | 192 (83.8%) | 75 (78.1%) | |
| Yes | 37 (16.2%) | 21 (21.9%) | 0.219 |
| Smoking history | |||
| No | 190 (83.0%) | 79 (82.3%) | |
| Yes | 39 (17.0%) | 17 (17.7%) | 0.883 |
| Diabetes history | |||
| No | 172 (75.1%) | 67 (69.8%) | |
| Yes | 57 (24.9%) | 29 (30.2%) | 0.321 |
| Gallbladder size | |||
| Normal | 167 (72.9%) | 62 (64.6%) | |
| Abnormal | 62 (27.1%) | 34 (35.4%) | 0.133 |
| Gallbladder wall thickness (mm) | |||
| ≤3 | 137 (59.8%) | 58 (60.4%) | |
| >3 | 92 (40.2%) | 38 (39.6%) | 0.921 |
| Gallstone number | |||
| 1 | 33 | 14 | |
| ≥2 | 196 | 82 | 0.968 |
| Gallstone diameter (mm) | |||
| <3mm | 49 (21.4%) | 18 (18.8%) | |
| 3-10mm | 112 (48.9%) | 54 (56.3%) | |
| >10mm | 68 (29.7%) | 24 (24.9%) | 0.479 |
| Gallstone shape | |||
| Sphere | 121 (52.8%) | 66 (68.8%) | |
| Irregular | 53 (23.1%) | 17 (17.7%) | |
| Sand-like | 55 (24.1%) | 13 (13.5%) | 0.240 |
| Bile duct stones | |||
| No | 175 (76.4%) | 76 (79.2%) | |
| Yes | 54 (23.6%) | 20 (20.8%) | 0.590 |
| Diameter of CBD (mm) | |||
| ≤10 | 193 (84.3%) | 84 (87.5%) | |
| >10 | 36 (15.7%) | 12 (12.5%) | 0.455 |
| ALT (U/L) | |||
| <150U/L | 180 (78.6%) | 83 (86.5%) | |
| ≥150U/L | 49 (21.4%) | 13 (13.5%) | 0.100 |
| AST (U/L) | |||
| <53.6U/L | 161 (70.3%) | 72 (75.0%) | |
| ≥53.6U/L | 68 (29.7%) | 24 (25.0%) | 0.391 |
| AST/ALT | |||
| <1.0 | 145 (63.3%) | 50 (52.1%) | |
| ≥1.0 | 84 (36.7%) | 46 (47.9%) | 0.059 |
| GGT (U/L) | |||
| <150 | 139 (60.7%) | 66 (68.8%) | |
| ≥150 | 90 (39.3%) | 30 (31.2%) | 0.170 |
| AKP (U/L) | |||
| <125 | 162 (70.7%) | 65 (67.7%) | |
| ≥125 | 67 (29.3%) | 31 (32.3%) | 0.587 |
| TBIL (mg/dL) | |||
| <1.4 | 151 (65.9%) | 67 (69.8%) | |
| ≥1.4 | 78 (34.1%) | 29 (30.2%) | 0.500 |
| IBIL (mg/dL) | |||
| <0.8 | 182 (79.5%) | 80 (83.3%) | |
| ≥0.8 | 47 (20.5%) | 16 (16.7%) | 0.422 |
| DBIL (mg/dL) | |||
| <1.0 | 196 (85.6%) | 83 (86.5%) | |
| ≥1.0 | 33 (14.4%) | 13 (13.5%) | 0.838 |
| WBC (×109/L) | |||
| <10 | 164 (71.6%) | 68 (70.8%) | |
| ≥10 | 65 (28.4%) | 28 (29.2%) | 0.887 |
| GRAN% (%) | |||
| <80 | 147 (64.2%) | 59 (61.5%) | |
| ≥80 | 82 (35.8%) | 37 (38.5%) | 0.641 |
P<0.05 was statistically significant.
AKP, Alkaline phosphatase; ALT, Alanine transaminase; AST, Aspartate transaminase; CBD, Common bile duct; DBIL, Direct bilirubin; GGT, Gamma-glutamyl transferase; GRAN%, Granulocyte%; IBIL, Indirect bilirubin; TBIL, Total bilirubin; WBC, White blood cell count.
Figure 1Flow chart of the study.
Figure 2Cumulative risk of being diagnosed as ABP in 816 individuals with symptomatic gallstones and followed for a median of 89 months [IQR 45.8-130.0 months].
Univariate and multivariate Cox analysis of the study cohort.
| Variables | Univariate analysisHR (95% CI) |
| Multivariate analysisHR (95% CI) |
|
|---|---|---|---|---|
| Age (year) | ||||
| ≥50 vs. <50 | 5.479 |
| 3.491 |
|
| Sex | ||||
| Male vs. Female | 2.844 |
| 1.250 | 0.604 |
| Alcoholic history | ||||
| Yes vs. No | 1.955 |
| 0.917 | 0.851 |
| Smoking history | ||||
| Yes vs. No | 1.941 | 0.05 | ||
| Diabetes history | ||||
| Yes vs. No | 5.378 |
| 4.585 |
|
| Gallbladder size | ||||
| Abnormal vs. Normal | 0.732 | 0.384 | ||
| Gallbladder wall thickness (mm) | ||||
| >3 vs. ≤3 | 0.308 |
| 0.195 |
|
| Gallstone number | ||||
| ≥2 vs. 1 | 4.394 |
| 1.559 | 0.572 |
| Gallstone diameter (mm) | ||||
| 3-10mm vs. <3mm | 0.267 |
| 0.311 |
|
| >10mm vs. <3mm | 0.402 |
| 0.248 |
|
| Gallstone shape | ||||
| Irregular vs. Sphere | 0.762 | 0.511 | 0.842 | 0.726 |
| Sand-like vs. Sphere | 2.086 |
| 1.018 | 0.965 |
| Coexisting CBD stones | ||||
| Yes vs. No | 3.522 |
| 2.382 |
|
| Diameter of CBD (mm) | ||||
| >10 vs. ≤10 | 0.397 | 0.397 | ||
| ALT (U/L) | ||||
| ≥150U/L vs. <150U/L | 1.809 | 0.550 | ||
| AST (U/L) | ||||
| ≥53.6U/L vs. <53.6U/L | 1.528 | 0.151 | ||
| AST/ALT | ||||
| ≥1.0 vs. <1.0 | 0.979 | 0.944 | ||
| GGT (U/L) | ||||
| ≥150 vs. <150 | 2.428 |
| 0.436 | 0.146 |
| AKP (U/L) | ||||
| ≥125 vs. <125 | 1.695 | 0.075 | ||
| TBIL (mg/dL) | ||||
| ≥1.4 vs. <1.4 | 2.273 |
| 1.049 | 0.926 |
| IBIL (mg/dL) | ||||
| ≥0.8 vs. <0.8 | 0.810 | 0.588 | ||
| DBIL (mg/dL) | ||||
| ≥1.0 vs. <1.0 | 2.214 |
| 4.867 |
|
| WBC (×109/L) | ||||
| ≥10 vs. <10 | 5.494 |
| 3.628 |
|
| GRAN% (%) | ||||
| ≥80 vs. <80 | 4.033 |
| 1.717 | 0.217 |
P<0.05 was statistically significant.
AKP, Alkaline phosphatase; ALT, Alanine transaminase; AST, Aspartate transaminase; CBD, Common bile duct; DBIL, Direct bilirubin; GGT, Gamma-glutamyl transferase; GRAN%, Granulocyte%; IBIL, Indirect bilirubin; TBIL, Total bilirubin; WBC, White blood cell count.
‘bold values’ means statistical significant values (<0.05).
Figure 3Independent risk factors for ABP in patients with gallstones.
Figure 4Nomogram conducted by Cox regression, including age, diabetes history, gallbladder wall thickness, gallstone diameter, coexisting CBD stones, DBIL and WBC in patients with symptomatic gallstones.
Figure 5Receiver operating characteristic curve of the nomogram in the study cohort.
Accuracy of prediction model in validation cohorts.
| Prediction | Actual observation | |
|---|---|---|
| ABP | Non-ABP | |
| ABP | 11 | 17 |
| Non-ABP | 4 | 64 |
Sensitivity of model: 73.3% (11/15).
Specificity of model: 79.0% (64/81)/
Figure 6The calibration curve and results of the DCA and the CIC analysis of the nomogram in the validation cohort. (A) Calibration curves represent the difference between the actual prediction and the ideal perfect prediction (45◦ line). (B) The DCA curve of the nomogram for predicting ABP. It revealed that the nomogram could obtain a greater net benefit than either the “treat all” or the “treat none” strategy. (C) The CIC curve of the nomogram for predicting ABP. The solid blue line (Number high risk) represents the number of ABP patients predicted using the nomogram at each threshold probability; the dotted red line (number high risk with event) represents the number of true-positive ABP patients at each threshold probability.